Oman Healthcare Market Report 2026: Pharmaceutical Intelligence, MOH Access, and Vision 2040 Strategy

The Oman healthcare market is estimated at USD 5.5–6.5 billion in 2026, growing at approximately 6.2% CAGR through 2030. Government healthcare expenditure accounts for approximately 70% of total spend, funded through Oman's oil revenues and supplemented by growing employer and private health insurance. Oman's population of 4.9 million — including a large expatriate workforce — creates a diverse healthcare demand profile.

The Oman pharmaceutical market is estimated at USD 520–580 million in 2026, growing at 6.5–7% CAGR. MOH Central Medical Stores supplies government hospitals; private pharmacies and private hospital chains serve the remainder. Oman imports approximately 97% of pharmaceutical requirements — local manufacturing is limited to a small number of generic producers. Branded specialty pharmaceuticals in oncology, diabetes, and cardiovascular disease represent the highest-value market segments.

The Directorate General of Pharmaceutical Affairs and Drug Control at MOH Oman manages drug registration. Registration follows a technical dossier review process aligned with WHO standards; CE or FDA clearance and reference registration in ICH countries expedite review. Timelines range from 12–24 months for initial registration. Formulary listing at MOH Central Medical Stores follows registration and requires a local agent with an active import license. BioNixus tracks MOH Oman registration status and formulary listing timelines across therapeutic categories.

Oman pharmaceutical market growth is driven by: (1) chronic disease burden — diabetes (19%), cardiovascular disease, and cancer incidence all exceed global averages; (2) Vision 2040's commitment to expanding health insurance coverage to all Oman residents, increasing retail pharmacy channel value; (3) private hospital sector growth as Aster, Badr Al Samaa, and international hospital groups expand specialty capacity; and (4) increased awareness and early diagnosis driven by national screening programs.

Oncology is Oman's fastest-growing pharmaceutical therapy area — the Sultan Qaboos Comprehensive Cancer Care and Research Centre expansion is creating new consumption capacity. Diabetes management (GLP-1 receptor agonists, insulin intensification) is structurally large given ~19% adult prevalence. Rare diseases have growing attention through Royal Hospital's genetics program. Immunology and biologics are expanding as private insurance formularies broaden coverage of specialty drugs.

BioNixus delivers longitudinal hospital consumption analogue analytics, payer and formulary committee qualitative boards, bilingual HCP trackers where relevant, tender and access intelligence aligned to MOH registration and hospital procurement at The Royal Hospital and national centres in Oman, KOL mapping, and adoption modelling for healthcare and life sciences. Teams receive decision-ready outputs cross-validated against EphMRA and BHBIA governance with GDPR-aligned multinational fieldwork coordinated from London and regional hubs.